The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

摘要: Summary Background Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied the setting of targeted therapy. We sought to validate International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model receiving next-line after progression on first-line Methods In this population-based study, we analysed who received at 19 centres Canada, USA, Greece, Japan, Singapore, South Korea, and Denmark. The primary endpoint was overall survival since initiation compared performance IMDC three-factor MSKCC used previously treated start Findings Between Jan 1, 2005, Nov 30, 2012, included 1021 Median 12·5 months (95% CI 11·3–14·3). Five six predefined factors (anaemia, thrombocytosis, neutrophilia, Karnofsky status [KPS] Interpretation can be applied therapy, addition validated populations has an improved is applicable a more contemporary patient cohort than that model. Funding DF/HCC Kidney Cancer SPORE P50 CA101942-01, Research Network Canadian Institute Health Research, Trust Family, Loker Pinard, Michael Brigham, Gerald DeWulf.